NCT03893799

A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

A Phase 1b Dose-escalating Study With RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Renibus Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with Stage 3/4 CKD.

Conditions

• Healthy Volunteers
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	RBT-1	Single intravenous administration

Timeline

• Start date: 2019-08-27
• Primary completion: 2020-04-22
• Completion: 2020-12-31
• First posted: 2019-03-28
• Last updated: 2025-08-07
• Results posted: 2025-08-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study